TD Asset Management’s Denali Therapeutics DNLI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $5.96M | Sell |
231,644
-24,122
| -9% | -$496K | 0.01% | 775 |
|
|
2026
Q1 | $4.91M | Sell |
255,766
-83,644
| -25% | -$1.66M | ﹤0.01% | 796 |
|
|
2025
Q4 | $5.6M | Sell |
339,410
-55,190
| -14% | -$932K | ﹤0.01% | 781 |
|
|
2025
Q3 | $5.73M | Sell |
394,600
-101,690
| -20% | -$1.46M | ﹤0.01% | 764 |
|
|
2025
Q2 | $6.94M | Buy |
496,290
+187,710
| +61% | +$2.64M | 0.01% | 717 |
|
|
2025
Q1 | $4.2M | Buy |
308,580
+42,828
| +16% | +$821K | ﹤0.01% | 810 |
|
|
2024
Q4 | $5.42M | Buy |
265,752
+21,200
| +9% | +$543K | ﹤0.01% | 784 |
|
|
2024
Q3 | $7.2M | Buy |
244,552
+65,400
| +37% | +$1.62M | 0.01% | 707 |
|
|
2024
Q2 | $4.16M | Buy |
179,152
+7,766
| +5% | +$149K | ﹤0.01% | 800 |
|
|
2024
Q1 | $3.52M | Buy |
171,386
+80,342
| +88% | +$1.51M | ﹤0.01% | 854 |
|
|
2023
Q4 | $1.95M | Sell |
91,044
-43,956
| -33% | -$871K | ﹤0.01% | 1020 |
|
|
2023
Q3 | $2.79M | Buy |
135,000
+50,578
| +60% | +$1.28M | ﹤0.01% | 866 |
|
|
2023
Q2 | $2.49M | Sell |
84,422
-3,900
| -4% | -$110K | ﹤0.01% | 910 |
|
|
2023
Q1 | $2.03M | Sell |
88,322
-10,887
| -11% | -$300K | ﹤0.01% | 976 |
|
|
2022
Q4 | $2.76M | Buy |
99,209
+5,086
| +5% | +$151K | ﹤0.01% | 896 |
|
|
2022
Q3 | $2.76M | Sell |
94,123
-27,100
| -22% | -$881K | ﹤0.01% | 907 |
|
|
2022
Q2 | $3.57M | Sell |
121,223
-11,814
| -9% | -$309K | ﹤0.01% | 849 |
|
|
2022
Q1 | $4.28M | Buy |
133,037
+10,700
| +9% | +$368K | ﹤0.01% | 861 |
|
|
2021
Q4 | $5.46M | Sell |
122,337
-4,500
| -4% | -$213K | ﹤0.01% | 844 |
|
|
2021
Q3 | $6.4M | Hold |
126,837
| – | – | 0.01% | 763 |
|
|
2021
Q2 | $6.47M | Sell |
126,837
-14,000
| -10% | -$866K | 0.01% | 765 |
|
|
2021
Q1 | $8.04M | Buy |
140,837
+7,013
| +5% | +$469K | 0.01% | 694 |
|
|
2020
Q4 | $11.2M | Buy |
133,824
+34,880
| +35% | +$2.11M | 0.01% | 555 |
|
|
2020
Q3 | $3.54M | Buy |
98,944
+41,337
| +72% | +$1.24M | ﹤0.01% | 795 |
|
|
2020
Q2 | $1.39M | Buy |
57,607
+24,900
| +76% | +$585K | ﹤0.01% | 959 |
|
|
2020
Q1 | $573K | Buy |
32,707
+8,707
| +36% | +$182K | ﹤0.01% | 1143 |
|
|
2019
Q4 | $418K | Hold |
24,000
| – | – | ﹤0.01% | 1275 |
|
|
2019
Q3 | $368K | Sell |
24,000
-500
| -2% | -$9.55K | ﹤0.01% | 1224 |
|
|
2019
Q2 | $509K | Buy |
24,500
+1,100
| +5% | +$24.6K | ﹤0.01% | 1178 |
|
|
2019
Q1 | $543K | Buy |
23,400
+500
| +2% | +$10.5K | ﹤0.01% | 1175 |
|
|
2018
Q4 | $473K | Buy |
22,900
+500
| +2% | +$9.07K | ﹤0.01% | 1237 |
|
|
2018
Q3 | $487K | Buy |
22,400
+6,000
| +37% | +$99.2K | ﹤0.01% | 1294 |
|
|
2018
Q2 | $250K | Hold |
16,400
| – | – | ﹤0.01% | 1367 |
|
|
2018
Q1 | $323K | Buy |
+16,400
| New | +$337K | ﹤0.01% | 1270 |
|
Other funds holding DNLI
VPM
VCM
TD Asset Management's DNLI Position: Q2 2026 in Review
TD Asset Management reduced its Denali Therapeutics (DNLI) stake by 9.4% in Q2 2026, selling an estimated $496K and leaving 231,644 shares worth $5.96M. The position accounts for 0.01% of the portfolio, ranked #775.
TD Asset Management first reported a position in DNLI in Q1 2018 and has held it in 34 quarters since. The position peaked at $11.2M in Q4 2020. 212 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.
- TD Asset Management held 231,644 shares of Denali Therapeutics worth $5.96M as of Q2 2026.
- TD Asset Management sold 24,122 Denali Therapeutics shares in Q2 2026, an estimated $496K.
- Denali Therapeutics made up 0.01% of TD Asset Management's portfolio in Q2 2026, its #775 holding.
- TD Asset Management first reported a position in Denali Therapeutics in Q1 2018 and has held it in 34 quarters since.
- TD Asset Management's Denali Therapeutics position peaked at $11.2M in Q4 2020.
- 212 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.
Based on TD Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.